Choosing the Right Diagnostic Pathway in Biopsy-Naive Patients With Suspected Prostate Cancer

JAMA Oncology ◽  
2021 ◽  
Vol 7 (4) ◽  
pp. 542
Author(s):  
Olivier Rouvière
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Pathway ◽  
The Right

Are We Worrying About the Right Men and Are the Right Men Feeling Worried? Conscious But Not Unconscious Prostate Anxiety Predicts Screening Among Men From Three Ethnic Groups

2011 ◽  
Vol 6 (1) ◽  
pp. 37-50 ◽  
Author(s):  
Nathan S. Consedine
Keyword(s):  
Prostate Cancer ◽  
Ethnic Groups ◽  
Mixed Model ◽  
Self Report ◽  
European American ◽  
Emotional Stroop Task ◽  
Screening Behavior ◽  
Minority Men ◽  
The Right ◽  
Mixed Model Anovas

Anxieties regarding cancer and screening have been consistently linked in prostate screening behavior with cancer-related anxieties generally thought to be higher among minority men. To date, however, the literature linking cancer anxieties to screening among diverse men remains predicated on self-reported anxiety. Research has yet to consider how “accurate” the reporting of anxiety may be among distinct groups of men or the possibility that anxiety may influence prostate cancer (PC) screening behavior through conscious and nonconscious channels; the current study tested for discrepancies between self-report and Stroop-ascertained general- and prostate-specific anxiety and their links to screening among 180 U.S.-born African American, U.S.-born European American, and immigrant Jamaican men. Men provided self-report information regarding trait and prostate-related anxiety and completed an emotional Stroop task. Mixed model ANOVAs showed that while U.S.-born African Americans had few discrepancies between self-report and Stroop-ascertained anxiety, Jamaicans reported greater PC anxiety than indicated by Stroop performance, while the opposite was true among U.S.-born Europeans. As expected, self-reported (but not Stroop-ascertained) PC anxiety predicted screening in multivariate analysis. Although men from different age and ethnic groups varied in the discrepancy between self-reported and Stroop-ascertained PC anxiety, the influence of avoidance-producing emotions appears to operate predominantly through conscious channels.

scholarly journals Primary hyperfibrinolysis as the presenting sign of prostate cancer: A case report

2016 ◽  
Vol 73 (9) ◽  
pp. 877-880 ◽  
Author(s):  
Andrijana Kulic ◽  
Zorica Cvetkovic ◽  
Vesna Libek
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Fibrinogen Level ◽  
Laboratory Diagnosis ◽  
Cancer Case ◽  
Normal Range ◽  
Normal Ranges ◽  
Assay Result ◽  
The Right ◽  
D Dimer

Introduction. A bleeding syndrome in the setting of primary hyperfibrinolysis in a prostate cancer patient is only 0.40? 1.65% of cases. The laboratory diagnosis of primary hyperfibrinolysis is based on the increase of biomarkers like D-dimer, fibrinogen split products, plasminogen, and euglobulin lysis test. These tests are not specific for primary hyperfibrinolysis. We reported a rare case of hemorrhagic syndrome caused by primary hyperfibrinolysis as the first clinical symptom of metastatic prostate cancer. Case report. A 64-year-old male was admitted to our hospital with large hematomas in the right pectoral and axillary areas (20 x 7 cm), right hemiabdomen (30 x 30 cm) and the left lumbal area, (25 x 5 cm). The patient had no subjective symptoms nor used any medication. Initial coagulation testing, prothrombin time (PT), and activated partial thromboplastin time (APTT) were within the normal range, while fibrinogen level was extremely low (1.068 g/L) (normal range 2.0?5.0) and the D-dimer assay result was high 1.122 mg/L (normal range < 0.23). The results obtained by rotation thrombelastometry pointed to primary fibrinolysis. Further clinical and laboratory examination indicated progressive malignant prostate disease. First line treatment for the patient was a combined administration of tranexamic acid (3 x 500 mg iv) and transfusion of ten units of cryoprecipitate (400 mL). Next day, fibrinolytic function measurements by rotation thrombelastometry were within the normal ranges. Fibrinogen level was normalized within two days (2.4 g/L). There were no newly developed hematomas. Conclusion. This case report shows primary hyperfibrinolysis with bleeding symptoms, which is an uncommon paraneoplastic phenomenon within expanded prostate malignancy. Rotation thrombelastometry in this severe complication helped to achieve the prompt and proper diagnosis and treatment.

scholarly journals Prostate cancer: what is the right message?

2015 ◽  
Vol 13 (4) ◽  
pp. 7-8
Author(s):  
Sidney Glina ◽  
Jacyr Pasternak
Keyword(s):  
Prostate Cancer ◽  
The Right

scholarly journals Diplopia as the First Sign of Gastric Carcinoma

2021 ◽  
pp. 870-874
Author(s):  
Suzanna L. Roohé ◽  
Ivan M. Gan ◽  
Kim van der Weerd ◽  
Boaz Lopuhaä ◽  
Robert M. Verdijk ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gastric Carcinoma ◽  
Vision Loss ◽  
Leptomeningeal Metastasis ◽  
Unknown Origin ◽  
Orbital Metastasis ◽  
Initial Manifestation ◽  
Eye Muscle ◽  
Lateralis Muscle ◽  
The Right

Orbital metastasis may be the initial manifestation of a malignancy of unknown origin. The primary locations of orbital metastasis are usually the lung, prostate, gastrointestinal tract, skin, kidney, eye, or thyroid gland. Metastasis of gastric carcinoma to an extraocular eye muscle is extremely rare. A solitary thickening in an extraocular eye muscle with no inflammatory features is suspect for a tumor. Symptoms such as diplopia, proptosis, ptosis, vision loss, or pain may be associated with an orbital malignancy. Our patient, a 67-year-old man known with radically resected prostate cancer, presented with complaints of vertigo with a tendency to fall, headache, and diplopia when looking to the right. As a coincidental finding, swelling of the rectus lateralis muscle of the left eye was observed on imaging. Extensive additional investigations showed that a gastric carcinoma with intraorbital and leptomeningeal metastasis was the cause. In conclusion, a solitary thickened extraocular eye muscle should be recognized in time and examined further.

scholarly journals An Incidental Finding of Situs Ambiguus with Polysplenia in an Asymptomatic 70-Year-Old Male

2021 ◽  
pp. 1-3
Author(s):  
Christopher Ambrogi ◽  
◽  
Madina Ndoye ◽  
Keyword(s):  
Prostate Cancer ◽  
Urinary Retention ◽  
Acute Urinary Retention ◽  
Incidental Finding ◽  
Anatomical Variation ◽  
Rare Condition ◽  
Situs Ambiguus ◽  
Abdominal Organs ◽  
The Right ◽  
Thoracic And Abdominal

The term “Situs ambiguus” describes the configuration when some, but not all thoracic and abdominal organs are abnormally positioned. It is commonly associated with polysplenia, or multiple spleens. 50-100% of situs ambiguus with polysplenia have associated cardiac malformations [1]. We present a 70 year old male who came to our hospital for complete, acute, urinary retention, and was found to have invasive prostate cancer. Incidentally, the liver was positioned on the left side, and the spleen was located on the right side. There were multiple perisplenic nodular formations with peripheral calcifications that had enhancement kinetics similar to those of the spleen, suggesting polysplenia. In low thoracic cuts, the tip of the heart was clearly on the left side. The presence of situs ambiguus with polysplenia in the absence of cardiac abnormalities makes this case a unique presentation of an already rare condition. Clinicians should regularly consider the possibilities of anatomical variation in their medical and surgical practices.

Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time

2018 ◽  
pp. 355-362 ◽  
Author(s):  
Daniel E. Spratt ◽  
Deaglan J. McHugh ◽  
Michael J. Morris ◽  
Alicia K. Morgans
Keyword(s):  
Prostate Cancer ◽  
New Technologies ◽  
Postoperative Radiotherapy ◽  
The United States ◽  
Common Disease ◽  
Recurrent Prostate Cancer ◽  
Systemic Treatments ◽  
Effect Of Therapy ◽  
New Gene ◽  
The Right

Biochemically recurrent prostate cancer is an increasingly common disease state, with more than 25,000 cases occurring annually in the United States. Fortunately, progress continues to be made to more effectively identify metastatic disease, optimize existing therapies, and develop new technologies and therapeutic strategies for the timing and delivery of systemic treatments to improve outcomes. This review covers three topics related to the diagnosis and treatment of men with biochemical recurrence (BCR). First, we provide an update on the state of the rapidly evolving field of molecular imaging and its place in practice. Second, we describe validated clinicopathologic methods to risk stratify patients with biochemically recurrent disease, including new gene expression classifiers, to personalize postoperative radiotherapy (RT) timing. Last, we define our approach to optimal management with systemic therapy, including identifying the patients who may benefit most and balancing the duration and timing of treatment with consideration of the effect of therapy on quality of life (QOL) and medical complications associated with treatment.

scholarly journals A Synchronous Diagnosis of Metastatic Male Breast Cancer and Prostate Cancer

2019 ◽  
Vol 7 ◽  
pp. 232470961984723
Author(s):  
Leila Moosavi ◽  
Phyllis Kim ◽  
An Uche ◽  
Everardo Cobos
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Male Breast Cancer ◽  
Breast Cancer Diagnosis ◽  
Male Breast ◽  
Breast Mass ◽  
Medical Attention ◽  
Cancer History ◽  
History Of ◽  
The Right

In this article, we present a patient diagnosed synchronously with metastatic male breast cancer and prostate cancer. This is a 63-year-old male and recent immigrant from Nigeria, who sought medical attention for progressively worsening of shortness of breath and acute progression of a chronic right breast mass. An invasive breast carcinoma was diagnosed by the core biopsy of the right breast mass. Within 2 months of his breast cancer diagnosis, the patient also was diagnosed with prostate adenocarcinoma after being worked up for urinary retention. By presenting this patient with a synchronous diagnosis with metastatic male breast cancer and prostate cancer, history of chronic right breast mass, and gynecomastia, we speculate on possible cancer etiologies and risk factors.

Sign in / Sign up

Export Citation Format

Share Document